GeoVax
GeoVax Labs is a clinical-stage biotechnology company developing MVA-vectored vaccines for mpox, smallpox, COVID-19, and hemorrhagic fevers, plus a GDEPT gene therapy (Gedeptin) for solid tumors, targeting U.S. government biodefense procurement and oncology indications.
- Company typePublic
- Founded2006
- HeadquartersSmyrna, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What GeoVax does
GeoVax Labs, Inc. (NASDAQ: GOVX) is a clinical-stage biotechnology company headquartered in Smyrna, Georgia (Atlanta metro) that develops vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers. The company operates two core technology platforms: a Modified Vaccinia Ankara (MVA) vaccine platform licensed from the U.S. NIH that generates virus-like particles in vivo to elicit both humoral and cellular immune responses, and a Gene-Directed Enzyme Prodrug Therapy (GDEPT) platform acquired from PNP Therapeutics and supplemented with combination-therapy IP licensed from Emory University. Lead clinical assets include GEO-MVA (a mpox/smallpox vaccine advancing to Phase 3 under EMA scientific advice with a planned Q4 2026 initiation), GEO-CM04S1 (a multi-antigen COVID-19 vaccine for immunocompromised patients in a BARDA-funded Phase 2b), and Gedeptin (a replication-deficient adenovirus-based gene therapy for solid tumors, with FDA Orphan Drug designation in head and neck cancer and a planned Phase 2 combination trial with immune checkpoint inhibitors in H2 2027).
The company is pre-revenue and monetizes primarily through non-dilutive government funding (BARDA Project NextGen award of up to $45M direct funding and up to $388M total program value with clinical research organization partner Allucent), periodic equity issuances, and future expectations of government procurement contracts for orthopox preparedness and biodefense, supplemented by potential licensing royalties from oncology assets. Manufacturing capability is being transitioned to a scalable, continuous AGE1.CR.pIX avian cell line licensed from ProBioGen AG, replacing legacy chicken embryonic fibroblast processes. Primary future buyers are federal health agencies (BARDA, CDC, Strategic National Stockpile) for vaccines and academic cancer centers for Gedeptin adoption. Customer concentration in future revenue is therefore structurally High.
GeoVax firmographics
Firmographics- Name
- GeoVax
- Legal name
- GeoVax Labs, Inc.
- Website
- https://geovax.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GeoVax Labs is a clinical-stage biotechnology company developing MVA-vectored vaccines for mpox, smallpox, COVID-19, and hemorrhagic fevers, plus a GDEPT gene therapy (Gedeptin) for solid tumors, targeting U.S. government biodefense procurement and oncology indications.
- Ownership category
- akta.pro rank
GeoVax industry classification
Industry- Product category
- Biotechnology Vaccines and Cancer Immunotherapies
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industries
- Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
Keywords
Where GeoVax is headquartered
LocationHeadquarters
- HQ city
- Smyrna
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GeoVax business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Vaccine Product Sales: Revenue expected from commercial sales of GEO-MVA vaccine for mpox and smallpox upon regulatory approval, targeting government procurement and public health markets.
- Gedeptin Oncology Licensing: Potential licensing revenue from Gedeptin technology for solid tumor treatment, including combination therapies with immune checkpoint inhibitors.
- Government Contracts & BARDA Funding: Funding from BARDA (up to $45 million) and other government agencies for clinical development of COVID-19 and other vaccines.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
GeoVax product offering
Product offeringCore offering
GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers. Its primary products are the GEO-MVA vaccine for mpox and smallpox (targeting Phase 3 in Q4 2026), the Gedeptin® gene-directed enzyme prodrug therapy for head and neck cancer (Phase 2 planned H2 2027 in combination with immune checkpoint inhibitors), and the GEO-CM04S1 next-generation COVID-19 vaccine for immunocompromised patients (BARDA-funded Phase 2b). All candidates are built on the company's proprietary MVA vector platform or its GDEPT oncology platform and are intended for sale or licensing to government health agencies, biodefense programs, and cancer-treatment institutions.
Product overview
GeoVax Labs, Inc. is a clinical-stage biotechnology company utilizing two core technology platforms to develop a portfolio of vaccines and immunotherapies. The Modified Vaccinia Ankara (MVA) platform is used for creating preventive vaccines against infectious diseases, while the Gene-Directed Enzyme Prodrug Therapy (GDEPT) platform powers its oncology programs. The product portfolio includes: GEO-MVA (the near-term priority mpox and smallpox vaccine advancing toward Phase 3), GEO-CM04S1 (a next-generation COVID-19 vaccine for immunocompromised patients), hemorrhagic fever virus vaccines (Ebola Zaire, Ebola Sudan, and Marburg), and Gedeptin® (a gene therapy for solid tumors, initially focused on head and neck cancers, now advancing to Phase 2 in combination with immune checkpoint inhibitors).
Differentiator
Problem solved
Functional benefit
Brands
- GEO-MVA: Modified Vaccinia Ankara (MVA) vaccine candidate targeting mpox and smallpox
- Gedeptin
- GEO-CM04S1
Products and services
- GEO-MVA GEO-MVA is a Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox, smallpox, and other orthopoxviruses, intended to address global MVA vaccine supply constraints and support civilian public health and biodefense stockpiles.
- Gedeptin® Gedeptin® is a novel patented gene therapy for solid tumors using Gene-Directed Enzyme Prodrug Therapy (GDEPT), in which a replication-deficient adenovirus vector delivers a nonhuman gene expressing an enzyme that converts inactive prodrug (fludarabine phosphate) into active antitumor compound in situ; it holds FDA Orphan Drug designation for head and neck cancers.
- GEO-CM04S1 GEO-CM04S1 is a next-generation MVA-vectored, multi-antigen COVID-19 vaccine candidate designed for immunocompromised patients, supported by BARDA Project NextGen funding with a head-to-head Phase 2b design vs. an FDA-approved mRNA vaccine.
- Hemorrhagic Fever Virus Vaccines Vaccine candidates targeting Ebola Zaire, Ebola Sudan, and Marburg viruses developed using the MVA vaccine platform, representing a strategic extension into global health security and biodefense against high-mortality hemorrhagic fevers; preclinical data have demonstrated protective immune responses and survival benefits in animal studies, though programs are not currently under active development.
- Gedeptin + Immune Checkpoint Inhibitor Combination Gedeptin + Immune Checkpoint Inhibitor (ICI) Combination is an exclusive worldwide in-licensed program from Emory University that combines Gedeptin gene therapy with ICI therapy to convert immunologically cold tumors into more immune-responsive tumors in head and neck squamous cell carcinoma.
Quantifiable outcome
- Phase 3 trial expected to enroll approximately 500 participants evaluating neutralizing antibody responses vs approved MVA vaccine
- +2 more outcomes
Companies that use GeoVax
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
GeoVax technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
GeoVax partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, major and minor.
- PNP Therapeutics, Inc.coreIn September 2021, GeoVax entered into an assignment and license agreement with PNP Therapeutics granting exclusive worldwide rights to develop and commercialize Gedeptin for all human diseases and conditions including solid tumors. The Gedeptin technology was developed with funding support from the National Cancer Institute (NCI), part of the NIH.
- Emory UniversitycoreGeoVax entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin in combination with Immune Checkpoint Inhibitors. The licensed technology supports the combination of GDEPT-based tumor debulking with checkpoint blockade.
- AllucentmajorClinical research organization supporting the BARDA-funded Phase 2b clinical study of GEO-CM04S1 next-generation COVID-19 vaccine candidate.
- ProBioGen AGcoreGeoVax licensed the AGE1.CR.pIX continuous avian cell line system from ProBioGen AG for manufacturing MVA-based vaccines. This advanced manufacturing process intends to significantly increase yield and volume capacity while reducing manufacturing costs.
- VaxxasminorGeoVax announced a research program to evaluate needle-free, self-administered GEO-MVA vaccine using Vaxxas microarray patch technology for potential distribution advantages.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
GeoVax competitors and assessment
Company assessmentDirect peers
- Bavarian Nordic: Danish biotech and the most direct competitor in the MVA/mpox/smallpox vaccine space with FDA-approved JYNNEOS (MVA-BN). Competes head-to-head with GeoVax's GEO-MVA in government stockpiling, public health preparedness, and commercial orthopoxvirus vaccine markets.
- Emergent BioSolutions: U.S. biodefense-focused company with ACAM2000 smallpox vaccine and a broader portfolio of medical countermeasures. Directly comparable as a competing orthopoxvirus vaccine supplier and biodefense procurement contractor for government stockpiles.
- SIGA Technologies: Specialty biodefense company with FDA-approved TPOXX (tecovirimat) smallpox antiviral and government stockpiling contracts. Comparable as a small-cap public biodefense-focused biotech competing for Strategic National Stockpile budgets alongside GeoVax.
- Tonix Pharmaceuticals: Clinical-stage biotech developing TNX-801, a horsepox-based vaccine for smallpox and mpox, with similar regulatory pathway and target market to GeoVax's GEO-MVA. Comparable as a small-cap public peer in the orthopoxvirus vaccine space.
- Chimerix: Clinical-stage biotech developing antiviral therapies including smallpox and other infectious disease countermeasures, with similar focus on government biodefense procurement and BARDA-funded development. Comparable as a small-cap infectious disease biotech targeting similar stockpiling customers.
- Barinthus Biotherapeutics (formerly Vaccitech): Vaccitech was a UK-based MVA platform company that developed the Oxford/AstraZeneca COVID-19 vaccine using a related simian adenovirus/MVA prime-boost approach. Now Barinthus Biotherapeutics, it represents the most direct MVA-platform peer with shared vector technology heritage and comparable infectious disease focus.
Broad incumbents
- Novavax: Larger clinical/commercial-stage vaccine company with Nuvaxovid (protein subunit COVID-19 vaccine) and a broader pipeline including influenza vaccines. Comparable as a competing COVID-19 vaccine developer for immunocompromised populations and a public vaccine platform peer, though at a substantially larger scale.
- Moderna: Leading mRNA vaccine company with Spikevax (COVID-19) and mpox vaccine candidate (mRNA-1769) in development. Comparable as a competitor in both COVID-19 immunocompromised vaccination and mpox vaccine development, though at vastly greater scale and resources.
Emerging players
- Replimune Group: Clinical-stage oncolytic immunotherapy company developing RP1, RP2, and RP3 for solid tumors including in combination with checkpoint inhibitors. Comparable as a small public clinical-stage biotech pursuing intratumoral/immunotherapy combinations for solid tumors, overlapping with GeoVax's Gedeptin strategy.
Others
- PharmaJet: Medical device company developing needle-free injection systems for vaccine delivery, comparable to GeoVax's Vaxxas microarray patch partnership. Relevant as a complementary/enabling technology partner in the vaccine delivery space rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
GeoVax social profiles
Digital presenceGeoVax financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeoVax leadership team
Management profileNumber of profiles
Profiles21 records
GeoVax funding detail
Funding detailFunding overview
Funding rounds13 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeoVax M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeoVax
What does GeoVax do?
GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers. Its primary products are the GEO-MVA vaccine for mpox and smallpox (targeting Phase 3 in Q4 2026), the Gedeptin® gene-directed enzyme prodrug therapy for head and neck cancer (Phase 2 planned H2 2027 in combination with immune checkpoint inhibitors), and the GEO-CM04S1 next-generation COVID-19 vaccine for immunocompromised patients (BARDA-funded Phase 2b). All candidates are built on the company's proprietary MVA vector platform or its GDEPT oncology platform and are intended for sale or licensing to government health agencies, biodefense programs, and cancer-treatment institutions.
Is GeoVax a public or private company?
GeoVax is a public company. It is classified as public and is currently operating.
When was GeoVax founded?
GeoVax was founded in 2006. It employs 11 to 50 people.
Where is GeoVax based?
GeoVax is headquartered in Smyrna, United States, in the North America region.
How does GeoVax make money?
Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are gedeptin Oncology Licensing and government Contracts & BARDA Funding.
Who are GeoVax's main competitors?
Direct peers on record are Bavarian Nordic, Emergent BioSolutions, SIGA Technologies, Tonix Pharmaceuticals, Chimerix and Barinthus Biotherapeutics (formerly Vaccitech). Broad incumbents are Novavax and Moderna. Replimune Group is listed as an emerging player. PharmaJet is listed as an others.
Does GeoVax have an API?
No public API is recorded for GeoVax.
What industry is GeoVax in?
GeoVax's product category is Biotechnology Vaccines and Cancer Immunotherapies. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 325414 and its SIC code is 2834.